ADC Therapeutics SA
ADCT3.120USD
-0.160-4.88%
Close 07/28, 16:00（ET）Quotes delayed by 15 min
309.44MMarket Cap
LossP/E TTM
More Details of ADC Therapeutics SA Company
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
Company Info
Ticker SymbolADCT
Company nameADC Therapeutics SA
IPO dateMay 15, 2020
Founded at2011
CEOMr. Ameet Mallik
Number of employees263
Security typeOrdinary Share
Fiscal year-endMay 15
AddressBiopole
CityEPALINGES
Stock exchangeNYSE Consolidated
CountrySwitzerland
Postal code1066
Phone41216530200
Websitehttps://adctherapeutics.com/
Ticker SymbolADCT
IPO dateMay 15, 2020
Founded at2011
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.58M
+1.60%
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
1.55M
-1.70%
Mr. Mohamed Zaki
Mr. Mohamed Zaki
Chief Medical Officer
Chief Medical Officer
642.33K
+50.70%
Mr. Jose (Pepe) Carmona
Mr. Jose (Pepe) Carmona
Chief Financial Officer
Chief Financial Officer
404.81K
+0.52%
Mr. Peter J. Graham
Mr. Peter J. Graham
Chief Legal and Compliance Officer and Secretary
Chief Legal and Compliance Officer and Secretary
361.04K
-11.63%
Dr. Peter Hug, Ph.D.
Dr. Peter Hug, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
180.50K
+26.54%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Independent Director
Non-Executive Independent Director
134.98K
+38.35%
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
99.40K
+38.06%
Mr. Robert W. (Bob) Azelby
Mr. Robert W. (Bob) Azelby
Non-Executive Independent Director
Non-Executive Independent Director
55.26K
+98.35%
Dr. Tyrell J. Rivers, Ph.D.
Dr. Tyrell J. Rivers, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.58M
+1.60%
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
1.55M
-1.70%
Mr. Mohamed Zaki
Mr. Mohamed Zaki
Chief Medical Officer
Chief Medical Officer
642.33K
+50.70%
Mr. Jose (Pepe) Carmona
Mr. Jose (Pepe) Carmona
Chief Financial Officer
Chief Financial Officer
404.81K
+0.52%
Mr. Peter J. Graham
Mr. Peter J. Graham
Chief Legal and Compliance Officer and Secretary
Chief Legal and Compliance Officer and Secretary
361.04K
-11.63%
Dr. Peter Hug, Ph.D.
Dr. Peter Hug, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
180.50K
+26.54%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Thu, Jun 19
Updated: Thu, Jun 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Redmile Group, LLC
15.80%
Prosight Capital
9.62%
HPWH TH AG
8.74%
Point72 Asset Management, L.P.
7.90%
OrbiMed Advisors, LLC
6.02%
Other
51.92%
Shareholders
Shareholders
Proportion
Redmile Group, LLC
15.80%
Prosight Capital
9.62%
HPWH TH AG
8.74%
Point72 Asset Management, L.P.
7.90%
OrbiMed Advisors, LLC
6.02%
Other
51.92%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
26.07%
Hedge Fund
18.79%
Corporation
15.04%
Investment Advisor
7.91%
Research Firm
7.20%
Individual Investor
6.59%
Private Equity
6.02%
Bank and Trust
0.83%
Insurance Company
0.02%
Other
11.53%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
208
88.44M
89.17%
-13.33M
2025Q1
217
80.51M
81.56%
-23.93M
2024Q4
219
81.03M
83.80%
-19.29M
2024Q3
223
79.78M
82.57%
-21.86M
2024Q2
215
76.61M
81.35%
-7.96M
2024Q1
177
59.13M
71.30%
-27.56M
2023Q4
169
58.32M
71.49%
-25.86M
2023Q3
180
68.48M
85.02%
-18.63M
2023Q2
182
74.11M
92.00%
-12.88M
2023Q1
185
75.45M
93.66%
-4.11M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Redmile Group, LLC
15.67M
15.8%
--
--
Mar 31, 2025
Prosight Capital
9.54M
9.62%
+28.00K
+0.29%
Mar 31, 2025
HPWH TH AG
8.67M
8.74%
-1.12M
-11.42%
May 15, 2025
Point72 Asset Management, L.P.
7.83M
7.9%
+7.83M
--
Jun 16, 2025
OrbiMed Advisors, LLC
5.97M
6.02%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.50M
4.54%
-88.38K
-1.93%
Mar 31, 2025
Oaktree Capital Management, L.P.
4.02M
4.05%
+4.02M
--
Apr 25, 2024
AstraZeneca (UK) Ltd.
4.01M
4.04%
--
--
Dec 31, 2023
Morgan Stanley & Co. LLC
2.96M
2.98%
-968.19K
-24.66%
Mar 31, 2025
Auven Therapeutics General LP
2.23M
2.25%
-4.10M
-64.75%
Apr 23, 2024
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
iShares Micro-Cap ETF
0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
iShares Biotechnology ETF
0.02%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 ETF
0.01%
View more
iShares Micro-Cap ETF
Proportion0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.02%
iShares Biotechnology ETF
Proportion0.02%
ProShares UltraPro Russell2000
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
iShares Russell 2000 Growth ETF
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
